Last updated on December 25, 2025
KUALA LUMPUR: IHH Healthcare Berhad (“IHH”) reported a resilient financial performance for the second quarter ended 30 June 2025, supported by stronger inpatient volumes and higher revenue intensity across key markets.
Group revenue rose 3% year-on-year (YoY) to RM6.3 billion, with EBITDA steady at RM1.4 billion. On a constant currency basis, revenue and EBITDA expanded 18% and 11% respectively, reflecting robust operational fundamentals.
Profit after tax and minority interests (PATMI) fell 29% YoY to RM443 million, mainly due to lower net monetary gains from Türkiye following the application of the MFRS 129 accounting standard, as well as deferred tax credits recognised in the prior year. Excluding exceptional items, PATMI stood at RM419 million, down 4% YoY.
IHH declared an interim dividend of 5 sen per share for FY2025, higher than the 4.5 sen paid last year.
“We reported resilient financial performance for Q2 2025, driven by an improvement in inpatient volumes and higher revenue intensity across key markets. Our transformation framework has allowed us to anticipate structural shifts from inpatient to daycare models, as already seen in Singapore and Malaysia,”
said Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare.
Q2 2025 Operational Highlights
- Inpatient admissions: 231,627 (+4% YoY)
- Lab tests conducted: 27 million (+7% YoY)
- Occupancy rate: 68%
Revenue growth was driven primarily by Malaysia and Türkiye & Europe, with Mount Elizabeth Hospital in Singapore undergoing phased reopening of beds in July and August after temporary closures.
H1 2025 Performance
For the first half of FY2025, revenue increased 5% YoY on sustained patient volumes, while EBITDA was flat. Excluding exceptional items, PATMI was RM844 million. The Group maintained a strong balance sheet with RM2.5 billion net cash generated from operations and RM1.5 billion in cash reserves.
Outlook
Looking ahead, IHH said it remains confident in long-term growth supported by healthcare megatrends and ongoing transformation initiatives.
The Group has embarked on a multi-year digital transformation, beginning with C+ERM rollouts in Singapore and India, and is prioritising seven strategic areas: clinical excellence, patient experience, new care models, operational excellence, payor engagement, workforce value, and technology adoption.
IHH emphasised that its geographically diversified portfolio across Malaysia, Singapore, Türkiye, India, Greater China, and Europe provides strong resilience against market-specific headwinds.
